Find generic entry opportunities
Anticipate generic drug launch
Proactively manage your pharmacy inventory
Drug patents …
… from Kazakhstan to Kalamazoo
Manage your formulary budget
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Abstract:||There are provided novel 1,4-dihydropyridine derivatives, particularly 2,6-dimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-.beta.-(N-benzyl-N-methylamino)ethyl ester and 5-methyl ester. The 1,4-dihydropyridine derivatives are characterized by cerebral vascular dilator activity.|
|Inventor(s):||Murakami; Masuo (Tokyo, JA), Takahashi; Kozo (Tokyo, JA), Iwanami; Masaru (Yokohama, JA), Fujimoto; Masaharu (Tokyo, JA), Shibanuma; Tadao (Asaka, JA), Kawai; Ryutaro (Shiraoka, JA), Takenaka; Toichi (Tokyo, JA)|
|Assignee:||Yamanouchi Pharmaceutical Co., Ltd. (Tokyo, JA)|
Patent Claim Types:|
see list of patent claims
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.